← All trials
NCT03692429
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2018
- Primary completion
- Oct 18, 2021
- Completion date
- Oct 18, 2034
- First posted
- —
- Last posted
- —
- Enrollment
- 36
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- CelyadLead sponsor
- Novella ClinicalCollaborator
- University of LondonOverall official - principal investigator
- University of South FloridaOverall official - principal investigator
- The Christie NHS Foundation TrustOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.